226 related articles for article (PubMed ID: 30304034)
1. Hippo signaling pathway is altered in Duchenne muscular dystrophy.
Vita GL; Polito F; Oteri R; Arrigo R; Ciranni AM; Musumeci O; Messina S; Rodolico C; Di Giorgio RM; Vita G; Aguennouz M
PLoS One; 2018; 13(10):e0205514. PubMed ID: 30304034
[TBL] [Abstract][Full Text] [Related]
2. Dystrophin-glycoprotein complex sequesters Yap to inhibit cardiomyocyte proliferation.
Morikawa Y; Heallen T; Leach J; Xiao Y; Martin JF
Nature; 2017 Jul; 547(7662):227-231. PubMed ID: 28581498
[TBL] [Abstract][Full Text] [Related]
3. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
[TBL] [Abstract][Full Text] [Related]
4. microRNA-10 and -221 modulate differential expression of Hippo signaling pathway in human astroglial tumors.
Aguennouz M; Polito F; Visalli M; Vita G; Raffa G; Oteri R; Ghazi B; Scalia G; Angileri FF; Barresi V; Caffo M; Cardali S; Conti A; Macaione V; Bartolotta M; Giorgio RD; Germanò A
Cancer Treat Res Commun; 2020; 24():100203. PubMed ID: 32777750
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
6. The Hippo pathway effector YAP is a critical regulator of skeletal muscle fibre size.
Watt KI; Turner BJ; Hagg A; Zhang X; Davey JR; Qian H; Beyer C; Winbanks CE; Harvey KF; Gregorevic P
Nat Commun; 2015 Jan; 6():6048. PubMed ID: 25581281
[TBL] [Abstract][Full Text] [Related]
7. Deubiquitinase YOD1: the potent activator of YAP in hepatomegaly and liver cancer.
Kim Y; Jho EH
BMB Rep; 2017 Jun; 50(6):281-282. PubMed ID: 28502290
[TBL] [Abstract][Full Text] [Related]
8. Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling.
Mana-Capelli S; McCollum D
J Biol Chem; 2018 Nov; 293(47):18230-18241. PubMed ID: 30266805
[TBL] [Abstract][Full Text] [Related]
9. Perturbation of muscle metabolism in patients with muscular dystrophy in early or acute phase of disease: In vitro, high resolution NMR spectroscopy based analysis.
Srivastava NK; Yadav R; Mukherjee S; Sinha N
Clin Chim Acta; 2018 Mar; 478():171-181. PubMed ID: 29278724
[TBL] [Abstract][Full Text] [Related]
10. miR-7977 inhibits the Hippo-YAP signaling pathway in bone marrow mesenchymal stromal cells.
Yoshida M; Horiguchi H; Kikuchi S; Iyama S; Ikeda H; Goto A; Kawano Y; Murase K; Takada K; Miyanishi K; Kato J; Kobune M
PLoS One; 2019; 14(3):e0213220. PubMed ID: 30835743
[TBL] [Abstract][Full Text] [Related]
11. Hippo/Yap signaling controls epithelial progenitor cell proliferation and differentiation in the embryonic and adult lung.
Lange AW; Sridharan A; Xu Y; Stripp BR; Perl AK; Whitsett JA
J Mol Cell Biol; 2015 Feb; 7(1):35-47. PubMed ID: 25480985
[TBL] [Abstract][Full Text] [Related]
12. Src Inhibits the Hippo Tumor Suppressor Pathway through Tyrosine Phosphorylation of Lats1.
Si Y; Ji X; Cao X; Dai X; Xu L; Zhao H; Guo X; Yan H; Zhang H; Zhu C; Zhou Q; Tang M; Xia Z; Li L; Cong YS; Ye S; Liang T; Feng XH; Zhao B
Cancer Res; 2017 Sep; 77(18):4868-4880. PubMed ID: 28754671
[TBL] [Abstract][Full Text] [Related]
13. Sphingosylphosphorylcholine regulates the Hippo signaling pathway in a dual manner.
Kemppainen K; Wentus N; Lassila T; Laiho A; Törnquist K
Cell Signal; 2016 Dec; 28(12):1894-1903. PubMed ID: 27634386
[TBL] [Abstract][Full Text] [Related]
14. RARγ Downregulation Contributes to Colorectal Tumorigenesis and Metastasis by Derepressing the Hippo-Yap Pathway.
Guo PD; Lu XX; Gan WJ; Li XM; He XS; Zhang S; Ji QH; Zhou F; Cao Y; Wang JR; Li JM; Wu H
Cancer Res; 2016 Jul; 76(13):3813-25. PubMed ID: 27325643
[TBL] [Abstract][Full Text] [Related]
15. Opposing roles of miR-21 and miR-29 in the progression of fibrosis in Duchenne muscular dystrophy.
Zanotti S; Gibertini S; Curcio M; Savadori P; Pasanisi B; Morandi L; Cornelio F; Mantegazza R; Mora M
Biochim Biophys Acta; 2015 Jul; 1852(7):1451-64. PubMed ID: 25892183
[TBL] [Abstract][Full Text] [Related]
16. miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis.
Kang W; Huang T; Zhou Y; Zhang J; Lung RWM; Tong JHM; Chan AWH; Zhang B; Wong CC; Wu F; Dong Y; Wang S; Yang W; Pan Y; Chak WP; Cheung AHK; Pang JCS; Yu J; Cheng ASL; To KF
Cell Death Dis; 2018 Jan; 9(2):92. PubMed ID: 29367737
[TBL] [Abstract][Full Text] [Related]
17. Oxidized low-density lipoprotein promotes vascular endothelial cell dysfunction by stimulating miR-496 expression and inhibiting the Hippo pathway effector YAP.
Hu J; Liu T; Zhang Z; Xu Y; Zhu F
Cell Biol Int; 2019 May; 43(5):528-538. PubMed ID: 30811087
[TBL] [Abstract][Full Text] [Related]
18. The Hippo signal transduction network in skeletal and cardiac muscle.
Wackerhage H; Del Re DP; Judson RN; Sudol M; Sadoshima J
Sci Signal; 2014 Aug; 7(337):re4. PubMed ID: 25097035
[TBL] [Abstract][Full Text] [Related]
19. Atheroprotective laminar flow inhibits Hippo pathway effector YAP in endothelial cells.
Xu S; Koroleva M; Yin M; Jin ZG
Transl Res; 2016 Oct; 176():18-28.e2. PubMed ID: 27295628
[TBL] [Abstract][Full Text] [Related]
20. The Hippo pathway regulator KIBRA promotes podocyte injury by inhibiting YAP signaling and disrupting actin cytoskeletal dynamics.
Meliambro K; Wong JS; Ray J; Calizo RC; Towne S; Cole B; El Salem F; Gordon RE; Kaufman L; He JC; Azeloglu EU; Campbell KN
J Biol Chem; 2017 Dec; 292(51):21137-21148. PubMed ID: 28982981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
